235 related articles for article (PubMed ID: 34767803)
1. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.
Murphy CC; Cirillo PM; Krigbaum NY; Cohn BA
Am J Obstet Gynecol; 2022 Jan; 226(1):132.e1-132.e14. PubMed ID: 34767803
[TBL] [Abstract][Full Text] [Related]
2. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
3. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
4. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Stetson B; Hibbard JU; Wilkins I; Leftwich H
Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
[TBL] [Abstract][Full Text] [Related]
5. The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Miller ES; Sakowicz A; Roy A; Liu LY; Yee LM
Am J Obstet Gynecol MFM; 2019 May; 1(2):144-147. PubMed ID: 32914089
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
7. 17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Eke AC; Sheffield J; Graham EM
Obstet Gynecol; 2019 Mar; 133(3):468-475. PubMed ID: 30741815
[TBL] [Abstract][Full Text] [Related]
8. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Tsur A; Leonard SA; Kan P; Datoc IA; Girsen AI; Shaw GM; Stevenson DK; El-Sayed YY; Druzin ML; Blumenfeld YJ
Am J Perinatol; 2023 Aug; 40(11):1158-1162. PubMed ID: 37100422
[TBL] [Abstract][Full Text] [Related]
9. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
10. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
[TBL] [Abstract][Full Text] [Related]
11. Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
Waters TP; Schultz BAH; Mercer BM; Catalano PM
Obstet Gynecol; 2009 Jul; 114(1):45-49. PubMed ID: 19546757
[TBL] [Abstract][Full Text] [Related]
12. In utero exposure to antiemetic and risk of adult-onset colorectal cancer.
Murphy CC; Cirillo PM; Krigbaum NY; Singal AG; Cohn BA
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36895101
[TBL] [Abstract][Full Text] [Related]
13. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
Shaamash AH; Ali MK; Attyia KM
J Obstet Gynaecol; 2020 Jul; 40(5):633-638. PubMed ID: 31670998
[TBL] [Abstract][Full Text] [Related]
15. In-utero exposure to antibiotics and risk of colorectal cancer in a prospective cohort of 18 000 adult offspring.
Murphy CC; Cirillo PM; Krigbaum NY; Singal AG; Jones DP; Zaki T; Cohn BA
Int J Epidemiol; 2023 Oct; 52(5):1448-1458. PubMed ID: 36692207
[TBL] [Abstract][Full Text] [Related]
16. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
17. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
18. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
19. Risks of cause-specific mortality in offspring of pregnancies complicated by hypertensive disease of pregnancy.
Hammad IA; Meeks H; Fraser A; Theilen LH; Esplin MS; Smith KR; Varner MW
Am J Obstet Gynecol; 2020 Jan; 222(1):75.e1-75.e9. PubMed ID: 31336073
[TBL] [Abstract][Full Text] [Related]
20. The dosing regimen for 17-hydroxyprogesterone caproate was suboptimal: lessons for future pharmacotherapy for pregnant women.
Caritis SN; Dodeja P; Sharma S; Zhao W; Venkataramanan R
Am J Obstet Gynecol; 2024 Apr; ():. PubMed ID: 38670444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
